3 active not recruiting, 3 completed, 2 recruiting. 8 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 8 | Active not recruiting 3, Completed 3, Recruiting 2 |
Follow Plasma Cell Myeloma: new trials by email Literature Review of Plasma Cell Myeloma trials Research Report on Plasma Cell Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma | Phase 3 | Recruiting | SWOG Cancer Research Network | 510 | 2023-10-12 | 2026-06-10 |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial Bortezomib, Daratumumab and Hyaluronidase-fihj, Dexamethasone - Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 1450 | 2021-02-24 | 2026-08-19 |
| Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma Isatuximab SAR650984, Lenalidomide, Dexamethasone - Plasma Cell Myeloma | Phase 3 | Active not recruiting | Sanofi | 337 | 2020-06-16 | 2025-12-12 |
| A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant Isatuximab SAR650984, Bortezomib, Lenalidomide - Plasma Cell Myeloma | Phase 3 | Active not recruiting | Sanofi | 475 | 2017-12-07 | 2026-05-04 |
| Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients isatuximab SAR650984, carfilzomib, dexamethasone - Plasma Cell Myeloma | Phase 3 | Completed | Sanofi | 302 | 2017-10-25 | 2026-02-09 |
| Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients Isatuximab, Pomalidomide, Dexamethasone - Plasma Cell Myeloma | Phase 3 | Completed | Sanofi | 307 | 2016-12-22 | 2025-01-17 |
| Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Bortezomib, Carfilzomib, Dexamethasone - Plasma Cell Myeloma | Phase 3 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 1087 | 2013-12-06 | 2026-10-05 |
| Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Total-Body Irradiation, Fludarabine Phosphate, Mycophenolate Mofetil - Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission | Phase 3 | Completed | Fred Hutchinson Cancer Center | 87 | 2003-10-01 | 2017-05-15 |
Multiple Myeloma (8) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Chronic-Phase (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Waldenstrom Macroglobulinemia (1)
Blood Protein Disorders (8) · Cardiovascular Diseases (8) · Hematologic Diseases (8) · Hemic and Lymphatic Diseases (8) · Hemorrhagic Disorders (8) · Hemostatic Disorders (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Neoplasms, Plasma Cell (8) · Paraproteinemias (8) · Vascular Diseases (8) · Bone Marrow Diseases (1)
Dexamethasone (7) · Lenalidomide (5) · Bortezomib (4) · isatuximab (4) · Calcium Dobesilate (3) · auricularum (3) · dexamethasone 21-phosphate (3) · dexamethasone acetate (3) · carfilzomib (2) · daratumumab (2) · Acetaminophen (1) · Cyclosporine (1) · Cyclosporins (1) · Diphenhydramine (1) · Methylprednisolone (1)
Sanofi (4) · ECOG-ACRIN Cancer Research Group (2) · Fred Hutchinson Cancer Center (1) · SWOG Cancer Research Network (1)
United States (8) · Italy (5) · Australia (4) · Czechia (4) · France (4) · Germany (4) · Greece (4) · Japan (4) · New Zealand (4) · Spain (4) · Turkey (Türkiye) (4) · Canada (3) · Denmark (3) · Hungary (3) · Poland (3)
Brenda Sandmaier (1) · Shaji K Kumar (1) · Shaji Kumar (1) · Sikander Ailawadhi (1)
PMID 36108425, PMID 38573925, PMID 31833394, PMID 32499241, PMID 32586908, PMID 32866432, PMID 33839618, PMID 34097854, PMID 34800109, PMID 35641409, PMID 36239134, PMID 36372355, PMID 37156782, PMID 37479547, PMID 37584290, PMID 38299578, PMID 38832972, PMID 39067465, PMID 40109195, PMID 41758929, PMID 42363804, PMID 42456135
2017 (2), U10CA180820 (2), 2016 (1), 2019 (1), 2023 (1), P01CA078902 (1), P30CA015704 (1), U10CA021115 (1), U10CA180888 (1), U24CA196172 (1)